← Browse by Condition
Medical Condition

advanced hepatocellular carcinoma

Total Trials
8
Recruiting Now
8
Trial Phases
Phase 3, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for advanced hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for advanced hepatocellular carcinoma?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for advanced hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced hepatocellular carcinoma?
advanced hepatocellular carcinoma research spans Phase 1 (3 trials), Phase 2 (3 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced hepatocellular carcinoma clinical trial?
Eligibility criteria for advanced hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
3
Phase 3
2
Top Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 2 trials
NRG Oncology 1 trial
Fujian Medical University 1 trial
Alnylam Pharmaceuticals 1 trial
Shenzhen University General Hospital 1 trial

Recruiting Clinical Trials

NCT07166406 Phase 3
Recruiting

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Enrollment
226 pts
Location
United States
Sponsor
NRG Oncology
View Trial →
NCT06363825 Phase 2
Recruiting

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Enrollment
57 pts
Location
China
Sponsor
Fujian Medical University
View Trial →
NCT06600321 Phase 1
Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Enrollment
158 pts
Location
United States, Italy...
Sponsor
Alnylam Pharmaceuticals
View Trial →
NCT05620706
Recruiting

Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma

Enrollment
20 pts
Location
China
Sponsor
Shenzhen University General Ho...
View Trial →
NCT06550921
Recruiting

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Enrollment
60 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06618664 Phase 3
Recruiting

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Enrollment
590 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT05797805 Phase 1, Phase 2
Recruiting

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Enrollment
178 pts
Location
United States, Canad...
Sponsor
Iterion Therapeutics
View Trial →
NCT05444088 Phase 1, Phase 2
Recruiting

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Enrollment
129 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology